Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Protein Kinase C Modulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Protein kinase C (PKC) is a family of phospholipid-dependent serine/threonine kinases. PKCs are involved in multiple signal transduction systems that control cell proliferation, differentiation, survival, invasion, migration, and apoptosis. PKC inhibitors act by inhibiting DAG (C1 domain-binding inhibitors), or by inhibiting ATP (C3 domain-binding inhibitors), or by inhibiting the substrate (C4 domain-binding inhibitors), whereas the PKC activators act by binding to the C1 domain. PKC inhibitors have been marketed for liver cancer, renal-cell carcinoma, thyroid cancer, and actinic keratosis. PKCs are also being targeted for neurological diseases such as Alzheimer’s disease, cardiovascular diseases such as heart failure, and infections. Takeda Pharmaceutical, Exelixis, Novartis, Mirati Therapeutics, Eli Lilly & Company, Pfizer, and Roche are some of the major players in the protein kinase C inhibitors market.
Key Market Developments:
Approved Drug Molecules and Brand Names for Protein Kinase C Modulators:
Drugs under the Pipeline for Protein Kinase C Modulators:
Clinical Activity and Developments of Protein Kinase C Modulators:
Currently, there are about 29 drug products in protein kinase C inhibitor, including 2 approved drug molecules, and others are in clinical trial phases.
Molecule Name |
Number of Studies |
Rydapt (Midostaurin) |
58 |
Kinenza (Enzastaurin) |
55 |
Sitravatinib (MGCD516) |
37 |
Sotrastaurin (AEB071) |
23 |
Arxxant (Ruboxistaurin oral) |
15 |
Ningetinib (CT053PTSA) |
7 |
Tigilanol tiglate (EBC-46) |
7 |
MS-553 |
5 |
Zanzalintinib (XL092) |
5 |
MRX2843 |
4 |
Zonalta (Z-Endoxifen hydrochloride) |
4 |
Bryostatin 1 (NSC 339555) |
4 |
Darovasertib (IDE196) |
4 |
KAI-1678 |
3 |
ONO-7475 |
2 |
PCUR-101 |
2 |
Q702 |
2 |
Tetradecanoylphorbol acetate (PD-616) |
2 |
AHT956 |
1 |
AR-13503 |
1 |
CC-90005 |
1 |
EXS4318 |
1 |
INCB81776 |
1 |
PF-07265807 |
1 |
RXDX-106 |
1 |
SKI-G-801 |
1 |
Ruboxistaurin topical (DBI-102) |
1 |
Cabozantinib is marketed for liver cancer, renal cell carcinoma, and thyroid cancer, and is in phase-III for non-small cell lung cancer and prostate cancer. Ingenol mebutate is used in the treatment of actinic keratosis. Enzastaurin is in phase-III for diffuse large B cell lymphoma, Ehlers-Danlos syndrome, glioblastoma. Sitravatinib is in phase-III for non-small cell lung cancer, ovarian cancer and renal cell carcinoma, and in phase-II/III for solid tumors. Ruboxistaurin is in phase-II for hyperpigmentation, melanosis, and skin disorders. Zanzalintinib is in phase-III for colorectal cancer and renal cell carcinoma.
Download Free Sample Report
Cabometyx (Cabozantinib tablet), Picato Gel (Ingenol mebutate) are the approved protein kinase C modulators in the market.
Takeda Pharmaceutical, Exelixis, Novartis, Mirati Therapeutics, Eli Lilly & Company, Pfizer, and Roche are some of the major players in the protein kinase C inhibitors market.
Major indications for liver cancer, renal-cell carcinoma, thyroid cancer, and actinic keratosis.
There are more than 20 molecules in the clinical development for protein kinase C modulators.
Key Market Players